RS Research, founded in 2015 by Rana Sanyal and Sena Nomak, is a pioneering therapeutics company specializing in the development of novel nanomedicines. These advanced medicines are designed using innovative drug delivery platforms aimed at treating cancer patients. The company operates within the biotechnology and pharmaceutical markets, focusing on creating cutting-edge solutions that address unmet medical needs in oncology. RS Research primarily serves healthcare providers, research institutions, and pharmaceutical companies. Its business model revolves around the research and development of proprietary drug delivery systems, which are then licensed or sold to larger pharmaceutical firms. Revenue is generated through licensing agreements, milestone payments, and royalties from commercialized products. The company has successfully raised 2 million Euros from ACT Venture Partners, a technology-focused venture capital fund, to support its clinical trials and further research initiatives.

Keywords: nanomedicines, drug delivery platforms, cancer treatment, oncology, biotechnology, pharmaceutical, clinical trials, venture capital, innovative therapies, academic spin-off.